Demcizumab

• CAT Number: I042442
• CAS Number: 1243262-17-0
• Molecular Weight: 145.65 (kDa)
• Purity: ≥95%

Demcizumab (Cat No.: I042442) is a humanized monoclonal antibody that targets Delta-like ligand 4 (DLL4), a key component of the Notch signaling pathway involved in angiogenesis and cancer stem cell maintenance. By inhibiting DLL4, demcizumab disrupts tumor vascular development and reduces cancer stem cell populations, impairing tumor growth and resistance. It has been studied in clinical trials for various cancers, including pancreatic and non-small cell lung cancer. Demcizumab represents a novel therapeutic strategy targeting the tumor microenvironment and cancer stem cell niches.

Reference

[1]. Smith DC, et al. A phase I dose escalation and expansion study of the anticancer stem cell agent demcizumab (anti-DLL4) in patients with previously treated solid tumors. Clin Cancer Res. 2014 Dec 15;20(24):6295-303.
[Content Brief]

[2]. Fischer M, et al. Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations. Cancer Res 2011;71:1520-5.
[Content Brief]

[3]. Hoey T, et al. DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell 2009;5:168–77.
[Content Brief]

[4]. Xiong H, et al. Spleen plays a major role in DLL4-driven acute T-cell lymphoblastic leukemia. Theranostics. 2021 Jan 1;11(4):1594-1608.
[Content Brief]